A Phase II Study of Radiotherapy and Concurrent Paclitaxel Chemotherapy in Breast-Conserving Treatment for Node-Positive Breast Cancer

Feasibility of Concurrent Radiotherapy and Paclitaxel-Based Chemotherapy after Conservative Surgery for Breast Cancer

“…Despite its rapid and easy application, operator dependency is considered its major disadvantage [23], which was overcome in our study by recruiting experienced doctors for assessment and analysis. The majority of our patients (82.5%) showed satisfactory objective and subjective response with only 4.8% showed poor cosmetic outcome, which is concordant with the results of Chen et al [22].…”

“…Such a finding may confirm the dermatological safety of our protocol, which is in accord with previous studies [22]. However, the final results of the ARCOSEIN trial [16] showed more skin toxicity, which may be attributed to the combined use of both doxorubicin and cyclophosphamide concurrently with radiotherapy.…”

“…There is no serious cardiac complications or increased incidence of lymphedema, which may be attributed to the application of CT based target delineation of supraclavicular and infraclavicular lymph nodes without axillary irradiation and with relative small clinical target volume (CTV) for nodal irradiation to ensure radiation coverage [22] and avoid unnecessary soft tissue irradiation outside target nodal areas.…”

Radiation/Paclitaxel Treatment of p53-Abnormal Non-Small Cell Lung Cancer Xenograft Tumor and Associated Mechanism

“…The therapeutic effect could be effectively established by a combination of radiation and paclitaxel through the upregulation of PTEN expression, PTEN activity, and activity of downstream molecules in NSCLC without p53. Although the antitumor effect of radiation and paclitaxel has been evaluated in lung cancer patients in clinical trials, [7][8][9] the molecular mechanism involved in the treatment, particularly its correlation with p53 or PTEN, remains unknown. In this study, we established a tumor xenograft animal model by using NSCLC cells expressing wild-type PTEN, but not p53.…”

“…5 Paclitaxel is a natural compound originally isolated from pacific yew tree bark and now used to treat a variety of cancers, including lung cancer. 6 Although a combination of radiation and paclitaxel therapy has been evaluated in lung cancer treatment in several clinical trials, [7][8][9] the molecular foundation responsible for radiation/paclitaxel therapy has not yet been elucidated. Recently, significant progress has been made in understanding the molecular mechanism of lung cancer.…”